BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Miravant (MRVT) To Initiate PHOTREX Confirmatory Phase III Clinical Trial In Europe; Global CRO Kendle Selected To Provide Clinical Development And Trial Management Services


10/19/2005 5:12:59 PM

SANTA BARBARA, Calif.--(BUSINESS WIRE)--March 10, 2005--Miravant Medical Technologies (OTCBB:MRVT), a pharmaceutical development company specializing in PhotoPoint(R) photodynamic therapy (PDT), today announced that it will conduct a confirmatory Phase III clinical trial for PHOTREX(TM) (rostaporfin, formerly known as SnET2) at investigational sites in Central and Eastern Europe (CEE) and the United Kingdom. Miravant has selected Kendle (Nasdaq:KNDL), a leading international contract research organization with locations worldwide, to provide clinical development services for the Phase III trial. The randomized, placebo-controlled study, reviewed by the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment, will evaluate a range of patients with wet age-related macular degeneration (AMD), including both classic and occult lesions. "Miravant selected Kendle based on its significant Phase III experience and expertise in Europe, particularly its patient access capabilities in CEE," said Gary S. Kledzik, Ph.D., chairman and chief executive officer. "These countries are proving to be desirable locations for conducting pharmaceutical clinical trials, with motivated, cost-effective research centers and high patient productivity. We are confident that Kendle's integrated study teams can efficiently manage the trial and satisfy our strategic regulatory requirements."

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES